Lyell Immunopharma Stockholders Approve Key Proposals

Lyell Immunopharma ( (LYEL) ) has shared an update.

On May 15, 2025, Lyell Immunopharma held its annual meeting of stockholders virtually, with 71.9% of shares represented, constituting a quorum. Stockholders voted on four proposals, including the election of Catherine Friedman as a director, ratification of Ernst & Young LLP as auditors, approval of executive compensation, and potential reverse stock split amendments, all of which were passed.

The most recent analyst rating on (LYEL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.

Spark’s Take on LYEL Stock

According to Spark, TipRanks’ AI Analyst, LYEL is a Neutral.

Lyell Immunopharma’s overall stock score reflects significant financial challenges, particularly due to the lack of revenue generation and operational losses. Technical analysis indicates a bearish trend, with the stock price below key moving averages and momentum indicators in oversold territory. Valuation metrics are also concerning, with a negative P/E ratio and no dividend yield, highlighting the need for strategic improvements to attract investor interest.

To see Spark’s full report on LYEL stock, click here.

More about Lyell Immunopharma

Lyell Immunopharma, Inc. operates in the biotechnology industry, focusing on developing innovative cell therapies for cancer treatment.

Average Trading Volume: 785,143

Technical Sentiment Signal: Sell

Current Market Cap: $122M

Learn more about LYEL stock on TipRanks’ Stock Analysis page.